NEWS 

06 DEC 2011    Launch of PIFA PLUSS PF4 Rapid Assay 

ABI is pleased to announce that its patented blood cell separator technology (the “Technology”) will be integrated into the Company’s PIFA Rapid Assay platform and launched into market in January 2012. The Technology enables the immediate separation of serum (the liquid component of blood) from a patient’s finger stick or venous whole blood sample and then introduces the extracted specimen into a rapid assay device to provide a real-time result. The initial introduction of the product line extension, branded under the trade name PIFA PLUSS, will expand the Company's franchise in the Heparin-Induced Thrombocytopenia (“HIT”) rapid testing market.

07 SEP 2011    Interim Results for the Six Months Ended 30 June 2011

The Company’s financial performance for the first half of 2011 demonstrated ABI's commitment to growth and operational efficiency.  This progress is best reflected by a 53% increase in Revenues and a 64% improvement in Gross Profit Margin over the same period in 2010. 

30 JUN 2011   US$3.2 Million Purchase Order – Revelar Free Radical Assay

ABI has secured a purchase order totaling US$3,242,200 to manufacture and supply Revelar breath tubes to Pulse Health, LLC under the Company’s Supply Agreement, as announced on 11 April 2011. This is the first purchase order under the Supply Agreement and manufacturing will commence immediately, from ABI’s New Jersey facility, with the majority of this order expected to be fulfilled during 2011.

23 JUN 2011   ABI to Sponsor Educational Webinar on Heparin-Induced Thrombocytopenia 

The Company is pleased to support an upcoming webinar entitled, ""Diagnosis and Treatment of Heparin-Induced Thrombocytopenia."  This CE-accredited session is being produced by Advance for Administrators of the Laboratory on Thursday, 14 July 2011 at 3:00 p.m. EST.

28 APR 2011   2010 Annual Report and Accounts

The Company's Annual Report and Accounts were posted to shareholders on 21 April 2011.  The Annual General Meeting of the Company will be held at 11.00 a.m. on 10 May 2011 at RiverWinds Community Center, 1000 RiverWinds Drive, Thorofare, New Jersey 08086, USA.

11 APR 2011   Preliminary Results for the Year Ended 31 December 2010

ABI's Chief Exectuive Officer, Thomas A. Nicolette and Chairman, Raymond F. Akers Jr., PhD are pleased to present the financial results for the year ended 31 December 2010.  Highlights include:

• Revenue increased 72% to $3.1 million (2009: $1.8 million)
• Gross Profit Margin increased by 18 basis points to 57.8% (2009: 40.3%)
• Adjusted Loss Before Tax substantially reduced by 74% to $1.2m (2009 loss: $4.6 million)

11 APR 2011   Supply Agreement and Acquisition of Breath Condensate Collection Technology

The Company is pleased to announce a strengthening of its relationship with Pulse Health, LLC (“Pulse”).  ABI renegotiated the technology transfer and supply agreement it had previously executed with Pulse in 2008. ABI purchased all Technology and intellectual property relating to non-invasive Breath Condensate Collection. ABI and Pulse also agreed to enter into a new Supply Agreement under which ABI will sell Pulse breath tubes for use in its Revelar devices.

04 APR 2011   Conclusion of First Heparin-Induced Thrombocytopenia Study

ABI announces the results of a study recently concluded at the University of Miami/Jackson Memorial Hospital.  The study compared ABI’s PIFA Heparin/PF4 Rapid Assay (“PIFA test”), as well as several different laboratory methods in the screening for heparin-induced thrombocytopenia (“HIT”) in critically ill patients.  The PIFA test correctly identified every positive patient and did not produce any “false negative” results, unlike the alternative ELISA test.

16 MAR 2011   ABI Granted Patent Protection for Rapid Blood Cell Separator Technology

The Company is pleased to announce that it has been granted patent protection in the United States, under patent 7,896,167 B2, for its novel blood cell separator technology ("the Technology").  The Technology facilitates rapid blood cell separation with small volumes of whole blood, including those obtained from finger stick samples. This sample preparation platform is a key element of products within ABI's portfolio and could also be integrated into rapid tests developed by the broader point-of-care diagnostic community.  

Government & Defense Procurement Information

All Products Proudly Manufactured in the USA

For additional information, please call +1 856 848 2116 or 1.800.451.TEST.